DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sun, Yujin | ko |
dc.contributor.author | Kim, Hoe Suk | ko |
dc.contributor.author | Kang, Sukmo | ko |
dc.contributor.author | Piao, Yin Ji | ko |
dc.contributor.author | Jon, Sangyong | ko |
dc.contributor.author | Moon, Woo Kyung | ko |
dc.date.accessioned | 2018-12-20T06:51:27Z | - |
dc.date.available | 2018-12-20T06:51:27Z | - |
dc.date.created | 2018-12-03 | - |
dc.date.created | 2018-12-03 | - |
dc.date.created | 2018-12-03 | - |
dc.date.issued | 2018-08 | - |
dc.identifier.citation | ADVANCED HEALTHCARE MATERIALS, v.7, no.21 | - |
dc.identifier.issn | 2192-2640 | - |
dc.identifier.uri | http://hdl.handle.net/10203/248286 | - |
dc.description.abstract | The feasibility of detecting breast cancer stem-like cells (BCSCs) with magnetic resonance imaging using extradomain-B of fibronectin (EDB-FN)-specific peptide (APT(EDB))-conjugated thermally cross-linked superparamagnetic iron oxide nanoparticles (APT(EDB)-TCL-SPIONs) is previously demonstrated. Here, doxorubicin (Dox)-loaded APT(EDB)-TCL-SPIONs (Dox@APT(EDB)-TCL-SPIONs) are generated and their theranostic ability in a BCSC xenograft mouse model is assessed. The Dox@APT(EDB)-TCL-SPIONs enable more efficient delivery of Dox to tumors than nontargeted Dox@TCL-SPIONs. Much greater inhibition of BCSC tumor growth is observed after treatment with the Dox@APT(EDB)-TCL-SPIONs than with either Dox@TCL-SPIONs or free Dox. Hypointense signals are observed in the majority of the mice in postcontrast but not precontrast T2*-weighted MR images of tumors 7 days after treatment with Dox@APT(EDB)-TCL-SPIONs. An inverse correlation is observed between signal intensity and both EDB-FN expression and response to chemotherapy. The data indicate Dox@APT(EDB)-TCL-SPIONs can detect BCSCs within tumors by targeting EDB-FN-expressing cells. These nanoparticles thus have theranostic potential in breast cancer. | - |
dc.language | English | - |
dc.publisher | WILEY | - |
dc.title | Magnetic Resonance Imaging-Guided Drug Delivery to Breast Cancer Stem-Like Cells | - |
dc.type | Article | - |
dc.identifier.wosid | 000449816200014 | - |
dc.identifier.scopusid | 2-s2.0-85052471031 | - |
dc.type.rims | ART | - |
dc.citation.volume | 7 | - |
dc.citation.issue | 21 | - |
dc.citation.publicationname | ADVANCED HEALTHCARE MATERIALS | - |
dc.identifier.doi | 10.1002/adhm.201800266 | - |
dc.contributor.localauthor | Jon, Sangyong | - |
dc.contributor.nonIdAuthor | Sun, Yujin | - |
dc.contributor.nonIdAuthor | Kim, Hoe Suk | - |
dc.contributor.nonIdAuthor | Piao, Yin Ji | - |
dc.contributor.nonIdAuthor | Moon, Woo Kyung | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | breast cancer stem cell | - |
dc.subject.keywordAuthor | doxorubicin | - |
dc.subject.keywordAuthor | extra domain B of fibronectin | - |
dc.subject.keywordAuthor | magnetic resonance imaging | - |
dc.subject.keywordAuthor | theranostics | - |
dc.subject.keywordPlus | IRON-OXIDE NANOPARTICLES | - |
dc.subject.keywordPlus | EXTRA DOMAIN-B | - |
dc.subject.keywordPlus | SOLID TUMORS | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | FIBRONECTIN | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PACLITAXEL | - |
dc.subject.keywordPlus | MARKER | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.